MITOTANE - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for mitotane and what is the scope of patent protection?

Mitotane is the generic ingredient in one branded drug marketed by Hra Pharma and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for mitotane. One supplier is listed for this compound.

Summary for MITOTANE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	23
Patent Applications:	7,449
What excipients (inactive ingredients) are in MITOTANE?	MITOTANE excipients list
DailyMed Link:	MITOTANE at DailyMed

Recent Clinical Trials for MITOTANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Center, Korea	Phase 2
Dr. Jurjan Aman	Phase 2
Exvastat Ltd.	Phase 2

See all MITOTANE clinical trials

Pharmacology for MITOTANE

Mechanism of Action	Cytochrome P450 3A4 Inducers

Medical Subject Heading (MeSH) Categories for MITOTANE

Antineoplastic Agents, Hormonal

Anatomical Therapeutic Chemical (ATC) Classes for MITOTANE

L01XX	Other antineoplastic agents
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for MITOTANE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hra Pharma	LYSODREN	mitotane	TABLET;ORAL	016885-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

EU/EMA Drug Approvals for MITOTANE

Subscribe to access the full database, or Sign Up
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
HRA Pharma Rare Diseases	Lysodren	mitotane	EMEA/H/C/000521 Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.	Authorised	no	no	no	2004-04-28
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.